EP0673385A4 - Zusammensetzungen aus menschlichem gap-43 und verfahren für ihre verwendung. - Google Patents

Zusammensetzungen aus menschlichem gap-43 und verfahren für ihre verwendung.

Info

Publication number
EP0673385A4
EP0673385A4 EP93920048A EP93920048A EP0673385A4 EP 0673385 A4 EP0673385 A4 EP 0673385A4 EP 93920048 A EP93920048 A EP 93920048A EP 93920048 A EP93920048 A EP 93920048A EP 0673385 A4 EP0673385 A4 EP 0673385A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
human gap
human
gap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93920048A
Other languages
English (en)
French (fr)
Other versions
EP0673385A1 (de
Inventor
Mark C Fishman
Howard Federoff
Mauricio Zuber
Stephen Strittmatter
Dario Valenzuela
Shi-Chung Ng
Edward Grabczyk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP0673385A1 publication Critical patent/EP0673385A1/de
Publication of EP0673385A4 publication Critical patent/EP0673385A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP93920048A 1992-08-13 1993-08-13 Zusammensetzungen aus menschlichem gap-43 und verfahren für ihre verwendung. Withdrawn EP0673385A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92892092A 1992-08-13 1992-08-13
US928920 1992-08-13
PCT/US1993/007643 WO1994004562A1 (en) 1992-08-13 1993-08-13 Mammalian gap-43 compositions and methods of use

Publications (2)

Publication Number Publication Date
EP0673385A1 EP0673385A1 (de) 1995-09-27
EP0673385A4 true EP0673385A4 (de) 1995-11-29

Family

ID=25457006

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93920048A Withdrawn EP0673385A4 (de) 1992-08-13 1993-08-13 Zusammensetzungen aus menschlichem gap-43 und verfahren für ihre verwendung.

Country Status (2)

Country Link
EP (1) EP0673385A4 (de)
WO (1) WO1994004562A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE317431T1 (de) 1998-11-24 2006-02-15 Pioneer Hi Bred Int Wurzelspezifische promotoren und ihre anwendung
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US7034109B2 (en) * 2000-10-13 2006-04-25 Christophe Bonny Intracellular delivery of biological effectors
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
KR20160023669A (ko) 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006948A1 (en) * 1988-12-22 1990-06-28 Fishman Mark C Mammalian gap-43 compositions and methods of use
WO1991013078A1 (en) * 1990-03-02 1991-09-05 Amoco Corporation Biosynthesis of carotenoids in genetically engineered hosts
WO1992018138A1 (en) * 1991-04-10 1992-10-29 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
WO1993006851A1 (en) * 1991-10-11 1993-04-15 The General Hospital Corporation Mammalian gap-43 compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006948A1 (en) * 1988-12-22 1990-06-28 Fishman Mark C Mammalian gap-43 compositions and methods of use
WO1991013078A1 (en) * 1990-03-02 1991-09-05 Amoco Corporation Biosynthesis of carotenoids in genetically engineered hosts
WO1992018138A1 (en) * 1991-04-10 1992-10-29 The General Hospital Corporation Mammalian gap-43 compositions and methods of use
WO1993006851A1 (en) * 1991-10-11 1993-04-15 The General Hospital Corporation Mammalian gap-43 compositions and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO9404562A1 *
Y. SUDO ET AL.: "Palmitoylation alters protein activity: blockade of G0 stimulation by GAP-43", EMBO JOURNAL, vol. 11, no. 6, EYNSHAM, OXFORD GB, pages 2095 - 2102 *

Also Published As

Publication number Publication date
EP0673385A1 (de) 1995-09-27
WO1994004562A1 (en) 1994-03-03

Similar Documents

Publication Publication Date Title
DE69637691D1 (de) Azeotropähnliche zusammensetzungen und ihre verwendung
DE69638056D1 (de) Azeotropähnliche zusammensetzungen und ihre verwendung
FI962246A7 (fi) Apoptoosia inhiboivat koostumukset, koostumusten puhdistusmenetelmät j a niiden käyttö
CY2010015I2 (el) Φθοροαλκοξυ-υποκατεστημενα βeναμιδια και η χρησιμοποιηση τους σαν κυκλικοι-νουκλεοτιδικοι αναστολεις φωσφοδιεστερασης
DE69519235D1 (de) Hämorrhoidenzusammensetzungen und verfahren zur verwendung
DE69313337D1 (de) Infrarotsensor und Verfahren für dessen Herstellung
ATE305792T1 (de) Grossflächige transplantate aus submucosalem gewebe und verfahren für ihre herstellung
DE69708657D1 (de) Taillenband für wegwerfunterwäsche und verfahren zu seiner herstellung
DE69525676D1 (de) Polyurethan-Zusammensetzungen, ihre Herstellung und Verwendung
DE69119301D1 (de) Hydrazincarboxamidderivate, Verfahren für ihre Herstellung und ihre Verwendung
DE69737053D1 (de) Chip-Widerstand und Verfahren zu dessen Herstellung
DE69733688D1 (de) Transformation der zygote und regeneration der transformierten maispflanzen aus isolierten embryosäcken
ATA102392A (de) Topisches terbinafinpräparat und verfahren zu seiner herstellung
DE69213064D1 (de) Thermoelektrisches Wandlerglied und Verfahren zu seiner Herstellung
DE69326424D1 (de) Gelierzusammensetzungen zur Verwendung in Ölfeldern
EP0673385A4 (de) Zusammensetzungen aus menschlichem gap-43 und verfahren für ihre verwendung.
DE69225439D1 (de) Verdichter und Verfahren zu seiner Herstellung
DE69711648D1 (de) Antimikrobielle zusammensetzung und verfahren zu ihrere herstellung
DE69326815D1 (de) Zweitakt schmiermittel und verfahren zu seiner verwendung
KR970703779A (ko) 건강 조성물(health composition)
DE69606044D1 (de) Synergistische herbizide zusammensetzung und verfahren zu ihre verwendung
DE69620914D1 (de) Perfluoralkoxycycloalkancarbonylfluorid-zusammensetzungen und ihre verwendung
DE68906462D1 (de) Praeparat aus reiskleie und dessen verwendung.
DE69433156D1 (de) Varistor und Verfahren zu seiner Herstellung
DE69510228D1 (de) Piperidinessigsäurederivate und ihre verwendung als fibrinogenantagonistmittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950313

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C07K 5/10

A4 Supplementary search report drawn up and despatched

Effective date: 19951016

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRABCZYK, EDWARD SEC. ON GENOMIC STRUC/FUNCTION

Inventor name: NG, SHI-CHUNG

Inventor name: VALENZUELA, DARIO

Inventor name: STRITTMATTER, STEPHEN

Inventor name: ZUBER, MAURICIO

Inventor name: FEDEROFF, HOWARD

Inventor name: FISHMAN, MARK, C.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRABCZYK, EDWARD SEC. ON GENOMIC STRUC/FUNCTION

Inventor name: NG, SHI-CHUNG

Inventor name: VALENZUELA, DARIO

Inventor name: STRITTMATTER, STEPHEN

Inventor name: ZUBER, MAURICIO

Inventor name: FEDEROFF, HOWARD

Inventor name: FISHMAN, MARK, C.

17Q First examination report despatched

Effective date: 19971030

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980311